Pay-for-performance demo
This article was originally published in The Gray Sheet
Executive Summary
CMS' Physician Group Practice pay-for-performance demonstration realized $9.5 million in savings in its first year and saw significant quality-of-care improvements, the agency announces July 11. The three-year demo, which began in April 2005, has 10 participating practices. First year results were based on 10 quality measures for diabetes care, including blood sugar management and control. For the second year, groups added heart failure and coronary artery disease measures, and for the third year added breast and colorectal cancer screening and hypertension measures. Strategies among the groups, which are rewarded with 80% of the savings they achieve from quality improvements, include health information technology updates and better coordinated care. CMS is considering further expanding the project...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.